Blueprint Medicines Corp
NASDAQ:BPMC
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
68.37
120.5
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one BPMC stock under the Base Case scenario is 94.54 USD. Compared to the current market price of 94.63 USD, Blueprint Medicines Corp is Fairly Valued.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Blueprint Medicines Corp
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for BPMC cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Blueprint Medicines Corp
Balance Sheet Decomposition
Blueprint Medicines Corp
Current Assets | 903.5m |
Cash & Short-Term Investments | 763.6m |
Receivables | 85.1m |
Other Current Assets | 54.9m |
Non-Current Assets | 300m |
Long-Term Investments | 104.9m |
PP&E | 109m |
Other Non-Current Assets | 86.1m |
Current Liabilities | 243.8m |
Accounts Payable | 4.9m |
Accrued Liabilities | 133.2m |
Other Current Liabilities | 105.7m |
Non-Current Liabilities | 639.5m |
Long-Term Debt | 338.7m |
Other Non-Current Liabilities | 300.9m |
Earnings Waterfall
Blueprint Medicines Corp
Revenue
|
434.4m
USD
|
Cost of Revenue
|
-13m
USD
|
Gross Profit
|
421.4m
USD
|
Operating Expenses
|
-697.4m
USD
|
Operating Income
|
-276m
USD
|
Other Expenses
|
147.9m
USD
|
Net Income
|
-128.1m
USD
|
Free Cash Flow Analysis
Blueprint Medicines Corp
USD | |
Free Cash Flow | USD |
Blueprint Medicines reported robust growth for its flagship drug, AYVAKIT, generating $128.2 million in Q3, a 137% increase year-over-year. The company raised its 2024 revenue guidance to between $475 million and $480 million, reflecting strong patient additions and compliance. AYVAKIT is on track to exceed a $2 billion revenue opportunity. International markets are also performing well, and cash burn is expected to decline significantly. Blueprint is focused on expanding its mast cell therapy portfolio, including upcoming studies for BLU-808 and elenestinib, while enhancing patient outreach initiatives to solidify its market position and drive sustainable growth into 2025.
What is Earnings Call?
BPMC Profitability Score
Profitability Due Diligence
Blueprint Medicines Corp's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
Score
Blueprint Medicines Corp's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
BPMC Solvency Score
Solvency Due Diligence
Blueprint Medicines Corp's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Score
Blueprint Medicines Corp's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BPMC Price Targets Summary
Blueprint Medicines Corp
According to Wall Street analysts, the average 1-year price target for BPMC is 128.09 USD with a low forecast of 81.81 USD and a high forecast of 175.35 USD.
Dividends
Current shareholder yield for BPMC is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
BPMC Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Blueprint Medicines Corp. is a precision therapy company. The company is headquartered in Cambridge, Massachusetts and currently employs 495 full-time employees. The company went IPO on 2015-04-30. The firm delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib) to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer and other genomically defined cancers, and cancer immunotherapy. Its pipelines also include BLU-263 (KIT), AYVAKIT (avapritinib) (PDGFRA), BLU-701 (EGFR), BLU-945 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2) and BLU-852 (MAP4K1). The company is developing and commercializing avapritinib for the treatment of advanced SM, and developing avapritinib for the treatment of non-advanced SM. The firm is developing BLU-263, an investigational, orally available KIT inhibitor, for the treatment of non-advanced SM and other mast cell disorders.
Contact
IPO
Employees
Officers
The intrinsic value of one BPMC stock under the Base Case scenario is 94.54 USD.
Compared to the current market price of 94.63 USD, Blueprint Medicines Corp is Fairly Valued.